FTC Dems’ view on pharma deal raises eyebrows

The Federal Trade Commission’s approval of Bristol-Myers Squibb/Celgene last week drew opposition from its Democratic members, worrying some antitrust lawyers about an ideological divide but winning praise from other competition experts.

Get unlimited access to all Global Competition Review content